Piper Sandler Maintains Overweight on Crescent Biopharma, Lowers Price Target to $32
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Piper Sandler analyst Biren Amin maintains Crescent Biopharma (NASDAQ:CBIO) with a Overweight and lowers the price target from $35 to $32.
Piper Sandler analyst Biren Amin maintains Crescent Biopharma (NASDAQ:CBIO) with a Overweight and lowers the price target from $35 to $32.
